Vocera Communications, Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). Nothing new has been filed by managers of Vocera Communications, Inc. in twelve months, the latest record being from 23 February 2022.
Over the whole record (from 2016), the tally stands at no purchases and 281 sales.
Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
FY ended December 2021 · cache
25 of 537 declarations
Vocera Communications, Inc. (ticker VCRA) was a U.S.-based healthcare technology company focused on clinical communication and care coordination. It was formerly listed on the NYSE in the United States, but it is no longer an independent public company: Stryker announced the acquisition in January 2022 and completed the transaction on February 23, 2022. For investors, that distinction is essential. Any reference to Vocera today should be understood through its integration into Stryker’s medical and digital healthcare platform rather than as a standalone equity story.
Founded in 2000, Vocera built its business around one core challenge in hospitals: helping caregivers communicate quickly, securely, and with minimal friction across complex clinical environments. The company’s headquarters were in California, United States. Its offerings combined software, purpose-built hardware, and workflow tools designed to improve care-team coordination. The best-known element of its portfolio was a hands-free voice communications badge, supported by mobile applications, alerting software, and integrations with hospital information systems. This made Vocera especially relevant in acute-care hospitals, health systems, and other care settings where time-sensitive communication affects both patient safety and operational efficiency.
Vocera’s competitive position was based on specialization. Rather than competing as a broad enterprise software vendor, it focused on a niche but strategically important segment of digital healthcare: secure clinical communication. That focus allowed the company to differentiate on usability, reliability in mission-critical environments, and interoperability with heterogeneous hospital IT infrastructures. Its solutions were designed to reduce communication bottlenecks, support staff productivity, and help institutions improve clinical workflows. In market terms, Vocera became widely recognized as a leader in digital care coordination and communication, a positioning that ultimately made it attractive to a larger strategic buyer.
Stryker’s acquisition thesis reflected this logic. Stryker described Vocera as a complementary portfolio addition that would strengthen its Advanced Digital Healthcare capabilities and broaden its medical division’s technology stack. The deal also signaled the growing importance of software-enabled workflow solutions in healthcare, alongside traditional medical devices. As a result, Vocera’s recent corporate developments are primarily linked to post-acquisition integration into Stryker rather than independent public-company announcements.
Geographically, Vocera’s business was rooted in the United States but served hospital customers beyond the domestic market through Stryker’s broader global footprint. For investors analyzing the former VCRA, the key takeaway is that the company represented a high-value healthcare communications niche, with strong strategic relevance, but its standalone equity story ended with the 2022 acquisition by Stryker on the NYSE in the United States.
| Fiscal year end | Revenue | Net income | Diluted EPS | Filing |
|---|---|---|---|---|
| Dec 2021 | 234.2 m USD | -8.5 m USD | -0.25 USD | 10-K |
| Dec 2020 | 198.4 m USD | -9.7 m USD | -0.30 USD | 10-K |
| Dec 2019 | 180.5 m USD | -18.0 m USD | -0.57 USD | 10-K |
| Dec 2018 | 179.6 m USD | -9.7 m USD | n.d. | 10-K |
| Dec 2017 | 166.0 m USD | -10.9 m USD | -0.38 USD | 10-K |
Amounts in USD, as filed (forms 10-K, 20-F or 40-F). Source: SEC EDGAR.